Home > Historical Performance > Historical Transaction Report

Transaction Details

Company: Gilead Sciences
Yahoo Beta:1.26

Company Description:  Gilead discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific.

Purchase Date:26 Feb 2014 Sale Date:05 Oct 2016
Purchase Price:$84.22 Sale Price:$77.50
  --Split Adjusted:$84.22  --Split Adjusted:$77.50
Shares Purchased:100 Shares Sold:75
  --Split Adjusted:100  --Split Adjusted:75
Transaction Fee:$9.99 Transaction Fee:$10.12
Price Range (6 Months Prior):    Price Range (6 Months After):    
High$83.95 High$0.00
Date25 Feb 2014 Date01 Jan 1996
Low$58.74 Low$0.00
Date27 Aug 2013 Date01 Jan 1996
S&P (Purchase Date):$1,859.45 S&P (Sale Date):$2,162.07

Timing:  We bought near the six month high.
Reason:  The company is well-positioned in a growing segment of the industry and its new HIV medications will be more successful than the market currently believes.

Timing:  0
Reason:  We trimmed our position so that GILD represented only 5% of our portfolio value. Gilead's price dropped significantly following our initial purchase. We added to our position. The price has risen since then. GILD still has a strong market for several of its drugs, particularly for hepatitis treatment. However, several other companies are developing alternative therapies, which also made trimming our exposure prudent.

S&P Gain: 16.27 % Annualized Gain: 6.16%
Stock Gain: -7.98 % Annualized Gain: -3.25%

Net Holding Return ($): $-391.11
Net Holding Return (%): -6.18 %